Clinical Trials in Need of Diversity in Connecticut

Article ID: 674901

Released: 17-May-2017 12:05 PM EDT

Source Newsroom: Yale Cancer Center

  • Credit: Sujata Srinivasan

    Sherry Willingham of Hartford, left, a stage 3 invasive breast cancer survivor, talks about faith, positive thinking and “taking power back from the doctors.” Seated in the middle is Denise Patterson of Hartford, a breast cancer survivor currently in a clinical trial at Hartford Hospital, and Dawn White-Bracey, founder of the cancer support group Sisters’ Journey in New Haven.

Newswise — Edith Baker of Plainville faced a devastating reality that patients with advanced cancer inevitably confront: She had stopped responding to conventional treatment.

Radiation and chemotherapy could no longer contain her stage 4 bladder cancer. 

But there was a ray of hope. Baker’s oncologist at Saint Francis Hospital and Medical Center referred her to a clinical trial at UConn Health involving two immunotherapy drugs: the FDA-approved Keytruda (pembrolizumab) from Merck & Co., credited with successfully treating former President Jimmy Carter’s melanoma; and Epacadostat (IDO1 inhibitor), an experimental drug from Incyte Corp.

“There was nothing else out there for me,” Baker said. Now, a year later, the retired nurse is living a full life with minimal side effects.

 

Read the full article from The New Haven Register at http://www.nhregister.com/health/20170510/clinical-trials-in-need-of-diversity-in-connecticut

 


Comment/Share





Chat now!